Skip Navigation
Print This Page
Share this page: More

Supreme Court Rules on Landmark Gene Patent Case

Haig Kazazian
Dr. Haig Kazazian 

Beginning in 1995, in a genetics lab at the University of Pennsylvania, Haig Kazazian and his colleague Arupa Ganguly tested roughly 500 women per year for the breast-cancer-predicting genes BRCA1 and BRCA2.

In 1999, they received a "cease and desist" letter from Myriad Genetics, which had successfully patented the genes in 1998. In 2008, Kazazian and Ganguly became the first plaintiffs in the ACLU's case against Myriad and the U.S. Patent and Trademark Office.

The Supreme Court officially ruled on Association for Molecular Pathology v. Myriad Genetics, Inc. on June 13. Read about the ruling on Supreme Court's official blog.

Dr. Kazazian is now a professor at the Johns Hopkins University School of Medicine in the Institute of Genetic Medicine. He holds a gene patent of his own, but believes gene patenting should be limited to particular circumstances.

Dr. Kazazian: Comments on the Ruling

Additional Resources


Sign Up for e-News

Subscribe to the JHM Update for the latest news from Johns Hopkins Medicine.


Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

U.S. 1-410-464-6713 (toll free)
International +1-410-614-6424



© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer